Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Augmentation in restless legs syndrome: an eye tracking study on emotion processing.
Ellmerer P, Heim B, Stefani A, Peball M, Werkmann M, Holzknecht E, Bergmann M, Brandauer E, Sojer M, Zamarian L, Delazer M, Seppi K, Högl B, Poewe W, Djamshidian A. Ellmerer P, et al. Ann Clin Transl Neurol. 2020 Sep;7(9):1620-1627. doi: 10.1002/acn3.51144. Epub 2020 Aug 12. Ann Clin Transl Neurol. 2020. PMID: 32786065 Free PMC article.
Nabilone for non-motor symptoms of Parkinson's disease: a randomized placebo-controlled, double-blind, parallel-group, enriched enrolment randomized withdrawal study (The NMS-Nab Study).
Peball M, Werkmann M, Ellmerer P, Stolz R, Valent D, Knaus HG, Ulmer H, Djamshidian A, Poewe W, Seppi K. Peball M, et al. Among authors: ellmerer p. J Neural Transm (Vienna). 2019 Aug;126(8):1061-1072. doi: 10.1007/s00702-019-02021-z. Epub 2019 May 25. J Neural Transm (Vienna). 2019. PMID: 31129719 Free PMC article. Clinical Trial.
Non-Motor Symptoms in Parkinson's Disease are Reduced by Nabilone.
Peball M, Krismer F, Knaus HG, Djamshidian A, Werkmann M, Carbone F, Ellmerer P, Heim B, Marini K, Valent D, Goebel G, Ulmer H, Stockner H, Wenning GK, Stolz R, Krejcy K, Poewe W, Seppi K; Collaborators of the Parkinson's Disease Working Group Innsbruck. Peball M, et al. Among authors: ellmerer p. Ann Neurol. 2020 Oct;88(4):712-722. doi: 10.1002/ana.25864. Epub 2020 Aug 31. Ann Neurol. 2020. PMID: 32757413 Free PMC article. Clinical Trial.
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
Pagano G, Boess FG, Taylor KI, Ricci B, Mollenhauer B, Poewe W, Boulay A, Anzures-Cabrera J, Vogt A, Marchesi M, Post A, Nikolcheva T, Kinney GG, Zago WM, Ness DK, Svoboda H, Britschgi M, Ostrowitzki S, Simuni T, Marek K, Koller M, Sevigny J, Doody R, Fontoura P, Umbricht D, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. Front Neurol. 2021 Oct 1;12:705407. doi: 10.3389/fneur.2021.705407. eCollection 2021. Front Neurol. 2021. PMID: 34659081 Free PMC article.
Tit for Tat: Costly Punishment in Manifest Huntington's Disease.
Heim B, Peball M, Saft C, von Hein SM, Piater JM, Ellmerer P, Seppi K, Djamshidian-Tehrani A. Heim B, et al. Among authors: ellmerer p. Neurodegener Dis. 2021;21(3-4):74-78. doi: 10.1159/000520303. Epub 2021 Oct 27. Neurodegener Dis. 2021. PMID: 34706364 Free article.
25 results